What labs to monitor Monitoring is not a formality it is the mechanism through which a GH peptide protocol is optimised and kept safe
The focus in prior CETP studies was to increase HDL
The absolute risk is very low (estimated up to 1 in 10,000 users), and causality is not fully established
About This Guide Written and clinically approved by: Shadeia Younis, Independent Prescribing Pharmacist and Superintendent Pharmacist Last clinically reviewed: 19 July 2026 Next review due: 19 January 2027, or sooner if the SmPC, NICE or MHRA guidance changes This article is checked against current UK product information, NICE guidance, MHRA safety communications and Slinics clinical-governance procedures
Obesity and HS are closely linked: the prevalence of obesity is higher in patients with HS, and conversely, obesity may predispose individuals to develop HS